Moffitt Cancer Center has once again been awarded the National Cancer Institute’s highest designation, Comprehensive Cancer Center, with its highest ranking ever.
Moffitt Cancer Center is participating in a national pilot project being conducted by the American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC). The pilot project is testing a research site self-assessment tool and an implicit bias training program focused on increasing racial and ethnic diversity among cancer treatment trial participants.
In a new article published in the Journal of the National Cancer Institute, Moffitt Cancer Center researchers report that patients treated with immune checkpoint inhibitors have a higher self-reported quality of life than patients treated with other types of therapy.
Moffitt Cancer Center has joined Dana-Farber Cancer Institute to provide free screenings to eligible adults who are at a higher risk for having or developing multiple myeloma or other related conditions. This initiative is through the PROMISE Study, a national cancer screening/cohort program to help researchers understand who is at risk based on a number of factors. The goal is to detect multiple myeloma before it becomes symptomatic and to monitor those who are at increased risk in order to study and hopefully prevent the development of the disease.
In a new article published in JNCI Cancer Spectrum, Moffitt Cancer Center researchers describe a prediction model they have created that includes information calculated from computed tomography images that can identify non-small cell lung cancer patients who are not likely to respond to immunotherapy.
Researchers in Moffitt Cancer Center’s Lung Cancer Center of Excellence believe a combination of checkpoint inhibitors with adoptive cell therapy could be the answer for non-small cell lung cancer patients. Results of their investigator-initiated phase 1 clinical trial evaluating the checkpoint inhibitor nivolumab in combination with tumor infiltrating lymphocyte (TIL) therapy was published today in Nature Medicine.
In a new article published online ahead of print in the journal Cancer Research, Moffitt Cancer Center researchers demonstrate a link between the presence of cutaneous human papillomavirus and the incidence of squamous cell carcinomas and identify key characteristics of infection that may contribute to development of the disease.
In a new study published in Cell Chemical Biology, Moffitt Cancer Center researchers report their identification of a new target for the PARP inhibitor drug talazoparib and show that combination treatment with talazoparib and the WEE1 inhibitor adavosertib results in enhanced anti-cancer effects.
Zeynep Eroglu, M.D., assistant member of the Cutaneous Oncology Department at Moffitt Cancer Center, received the 2021 Cancer Clinical Investigator Team Leadership Award from the National Cancer Institute.
The National Cancer Institute has awarded the Lung Cancer Metabolism Working Group at Moffitt Cancer Center with a Research Program Project Grant (P01CA250984). The grant, which will provide more than $10.2 million over five years, will support team research with a focus on investigating lung cancer metabolism.
In a new article published in The Lancet Public Health, they report results from a first-of-its kind nationwide study evaluating a targeted intervention aimed at transforming dual users’ e-cigarettes from a product that might maintain smoking into a tool that can be used to aid smoking cessation.
In a new article published in the Journal for ImmunoTherapy of Cancer, Moffitt Cancer Center researchers show that PET/CT images can be used to measure levels of the PD-L1 biomarker of non-small cell lung cancer (NSCLC) patients in a non-invasive manner and, in turn, predict a patient’s response to therapy.
In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers reveal how different therapies impact the surrounding immune environment of metastatic melanoma tumors according to location and identify a rare population of immune cells that is associated with improved overall survival.
Moffitt Cancer Center, a national leader in cancer care and research and the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, is presenting new data from dozens of clinical research studies at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, the world’s largest clinical cancer research meeting. Moffitt investigators will lead 25 abstract presentations, five education sessions, two cancer-based panels and two clinical science symposia. The virtual meeting is June 4-8.
In a new study published in JAMA Dermatology, Moffitt Cancer Center researchers report on the mutation profile of acral nevi and describe differences between acral nevi and acral melanoma.
In a new article published in the journal Immunity, Moffitt Cancer Center researchers show that TIM-3 inhibits the STING signaling pathway in dendritic cells, thereby blocking their ability to elicit an immune response.
In a new article published in Nature Communications, Moffitt Cancer Center researchers show how the location of the tumor and spatial constraints put on it by the surrounding tissue architecture impact genetic heterogeneity of tumors.
Cervical cancer is a serious global health threat which kills more than 300,000 women every year. Recognizing this urgent public health issue, the editorial team of Preventive Medicine is publishing a special issue titled “From Science to Action to Impact: Eliminating Cervical Cancer,” which outlines the required courses of action to eliminate cervical cancer. Dr. Anna Giuliano and Dr. Linda Niccolai, two giants in the field of cervical cancer prevention research, served as guest editors for the issue.
In a new article published in Cancer Immunology Research, the Moffitt team shows that sequential administration of immunotherapy followed by targeted therapy prolongs anti-tumor responses in preclinical models and may be a potential treatment option for patients with advanced melanoma.
In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers show that various subtypes of lung cancer cells activate different signaling pathways in response to KRASG12C inhibitor treatment. These results may help identify potential combination therapy approaches and guide treatment decisions for lung cancer patients in the future.
In a new article featured on this month’s cover of Cancer Research, Moffitt Cancer Center researchers, in collaboration with Oxford University, report results from their study using mathematical modeling to show that cell turnover impacts drug resistance and is an important factor that governs the success of adaptive therapy.
In a new article published in Nature, Moffitt Cancer Center researchers demonstrate why some ovarian cancer patients evolve better than others and suggest possible approaches to improve patient outcomes.
In a new study published in Blood, the official journal of the American Society of Hematology, Moffitt researchers show that immune dysregulation can directly affect the efficacy of CAR T therapy in patients with diffuse large B-cell lymphoma.
Moffitt Cancer Center is leading a national, multicenter clinical trial investigating a new therapy option for this group of patients. It builds upon the standard of care therapy, combining eprenetapopt (APR-246) with the chemotherapy azacitidine. Results of the phase 1b/2 trial to determine the safety, recommended dose and efficacy of the combination therapy were published in the Journal of Clinical Oncology.
mechanism available to pathogenic microbes – the ability to exchange and recombine genetic material between different cells. However, in a new article published in Nature Ecology & Evolution, Moffitt Cancer Center researchers demonstrate that this belief is wrong and that cancer cells are capable of exchanging and recombining their genetic material with each other through a mechanism mediated by cell fusions.
To better understand the conditions that select for the Warburg Effect and the mechanisms where cells can express this metabolic adaptation, Moffitt researchers subjected nonmalignant cells to the harsh tumor microenvironment that is present during early carcinogenesis, known as ductal carcinoma in situ. In a new research article published in the Proceedings of the National Academy of Sciences, the Moffitt team shows that these conditions select for cells to express a Warburg Effect.
In an article published in Cell Metabolism, Moffitt Cancer Center researchers report on a newly discovered biochemical pathway that protects cells from a type of cell death called ferroptosis.
A new study suggests a link between toxoplasma gondii (T. gondii) infection and the risk of glioma, a type of brain cancer, in adults. The report, appearing in the International Journal of Cancer, finds that people who have glioma are more likely to have antibodies to T. gondii (indicating that they have had a previous infection) than a similar group that was cancer free.
In order to improve their understanding of how CTCL develops in hopes of developing new therapies, a team of Moffitt immunologists and hematologists conducted a series of studies. In an article published in The Journal of Clinical Investigation, they demonstrate that decreased expression of the protein SATB1 contributes to CTCL development and that drugs that cause SATB1 to become re-expressed may be potential treatment options for this disease.
Moffitt Cancer Center researchers conducted studies to determine if genomic heterogeneity in tumors from grade 4/5 prostate cancer patients can be exploited to identify patient subsets that are at higher risk for lethal outcomes and that may benefit from targeted treatment strategies. Their results were published in the journal European Urology.
Because they spend most of their time in their labs, basic science researchers rarely get to meet the patients who benefit most from their work. A group at Moffitt Cancer Center decided to change that, and with the creation of the Patient Researcher Forum, the cancer center has found a way for researchers and patients to engage with each other.
Moffitt Cancer Center researchers are working to improve CAR T responses and make those responses more long-lasting for patients. In a new article published in Cancer Immunology Research, the team shares its findings, which show alterations to a specific domain of the chimeric antigen receptor enhances CAR T-cell activity and survival.
In a new article published in Clinical Cancer Research, Moffitt Cancer Center researchers describes the immune-oncologic differences in prostate cancer tumors of African American men and how those variations may be exploited to develop more personalized treatment approaches for this population.
In a new article published in Nature Communications, Moffitt Cancer Center researcher demonstrate how a deep learning model using positron emission tomography/computerized tomography radiomics can identify which non-small cell lung cancer patients may be sensitive to tyrosine kinase inhibitor treatment and those who would benefit from immune checkpoint inhibitor therapy.
In a new article published in the journal Nature Communications, Moffitt Cancer Center researchers describe how the protein TAp63 controls levels of RNA molecules, which subsequently connects the activities of p53 and AKT to promote disease progression.
In a new article published in the Journal of Investigative Dermatology, Moffitt researchers identify erythropoietin-producing hepatocellular receptor A2 (EphA2) as a driver of metastasis and BRAF-MEK inhibitor resistance in melanoma.
In a new article published in Nature Communications, Moffitt Cancer Center researchers describe a novel acidic niche within lymph nodes that plays an integral role in regulating T cell activation.
In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers identify possible factors that could help physicians know if patients are at higher risk for severe adverse events before they receive CAR T therapy.
In a new study published in Nature Scientific Reports, Moffitt Cancer Center researchers have shown how the use of radiomics can improve lung cancer screening by identifying early stage lung cancer patients who may be at high risk for poorer outcomes, and therefore require aggressive follow-up and/or adjuvant therapy.
Researchers in the Center of Excellence for Evolutionary Therapy at Moffitt Cancer Center want to better understand what is happening in the tumor microenvironment to drive prostate cancer to become aggressive and grow rapidly. In a new article published in Nature Ecology & Evolution, the research team provides a closer look at a multiscale mathematical model they developed to analyze integrated biologic and pathologic data to determine tumor aggressiveness.
Moffitt Cancer Center organized a consortium of 16 cancer treatment facilities across the U.S. that offer Yescarta as a standard-of-care therapy for patients with relapsed/refractory large B cell lymphoma. They wanted to determine if the safety and effectiveness seen in the ZUMA-1 clinical trial were similar for patients treated with the now commercially available CAR T therapy. Their findings were published in the Journal of Clinical Oncology.
In a new article published in the journal Immunity, Moffitt Cancer Center researchers reveas how protein-signaling pathways associated with cellular stress processes turn myeloid cells into tumor-promoting players. They also suggest that targeting the PERK protein may be an effective therapeutic approach to reactivate the immune system and boost the effectiveness of immunotherapy.
In an article published in Nature Communications, Moffitt Cancer Center researchers provide a closer look at a mathematical model and data showing that individual patient alterations in the prostate-specific antigen (PSA) biomarker early in cancer treatment can predict outcomes to later treatment cycles of adaptive therapy.
Researchers at Moffitt Cancer Center want to devise better therapeutic strategies for patients with cutaneous squamous cell carcinoma (cuSCC) by improving their understanding of how the disease develops. In a new article published online ahead of print in the journal Cancer Research, Moffitt scientists report on their identification of potential therapeutic targets for cuSCC.
Researchers at Moffitt Cancer Center are trying to identify alternative strategies to treat non-small cell lung cancer. (NSCLC) In a new article published online in Scientific Reports, they highlight how targeting the histone deacetylase HDAC11 may be a novel therapeutic strategy for NSCLC.
In a new article published online ahead of print in Cancer Research, members of Moffitt’s Center of Excellence for Evolutionary Therapy present a case study of an adaptive treatment approach based on evolutionary principles in prostate cancer and suggest that these strategies may provide a path toward improved multidrug adaptive therapies.
Immunotherapy has become a standard treatment approach for several types of cancer, including melanoma. However, tumors can escape immune cell detection even with the use of immunotherapies. In a new study published in Cancer Immunology Research, Moffitt Cancer Center researchers, in collaboration with the University of Miami’s Miller School of Medicine, describe a cellular mechanism that controls tumor cell recognition by immune cells.
Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). Despite these changes, many patients still develop progressive disease after ICI treatment. In a new study published in Clinical Cancer Research, Moffitt Cancer Center researchers describe promising results from an early clinical trial that may offer patients who progress after ICI an additional treatment option.
A personalized approach to cancer treatment has become more common over the last several decades, with numerous targeted drugs approved to treat particular tumor types with specific mutations or patterns. However, this same personalized strategy has not translated to radiation therapy, and a one-size-fits-all approach for most patients is still common practice. Moffitt Cancer Center researchers hope to change this mindset for radiation treatment with the development of a genomically-based model that can optimize and personalize a radiation dose to match an individual patient’s needs.